[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"joint-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:joint-diseases":414},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,58,91,124,154,178,202,231,253,294,329,353,377],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100407038",false,"NCT04580225","Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)","PARTE","Inclusion Criteria:\n\n* Participant has a stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) wrist and is a surgical candidate for the included surgical interventions\n\nExclusion Criteria:\n\n* Participant has been diagnosed with other forms of wrist arthritis other than SLAC or SNAC\n* Participant has significant arthritis of the ipsilateral hand\u002Ffinger joint(s), major joint trauma, previous major wrist surgery, infection or neuromuscular pathology affecting the function of the ipsilateral upper extremity or ability to make a fist\n* Participant has a physical or mental health condition preventing completion of consent or questionnaires\n* Participant does not speak\u002Fread\u002Funderstand English\n* Participant has no fixed address or means of contact\n* Participant is unwilling to complete necessary follow-ups\n* Surgeon concludes that eligible salvage techniques are not appropriate at the time of surgery (based on injury characteristics or concomitant wrist pathology)","ALL","18 Years","75 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized clinical trial (RCT) aims to compare clinical and radiographic outcomes of different partial wrist fusion techniques in participants with post-traumatic wrist arthritis. Participants with stage II or III scapholunate advanced collapse (SLAC) or scaphoid nonunion advanced collapse (SNAC) who meet the eligibility criteria will be randomly assigned to one of two parallel groups: Group A (partial wrist arthrodesis without triquetral excision i.e. four-corner arthrodesis), or Group B (partial wrist arthrodesis with triquetral excision i.e. three-corner or capitolunate arthrodesis with triquetral excision). The results of this study will provide evidence to guide surgeons in determining the ideal wrist fusion technique in the management of patients with post-traumatic wrist arthritis requiring surgery.",[26,27,28,29,30,31,32,33],"Wrist Arthritis","Wrist Arthropathy","Scapholunate Advanced Collapse","Scaphoid Nonunion","Post-traumatic; Arthrosis","Arthritis","Musculoskeletal Diseases","Joint Diseases",[35,36,37,38,39,40,41,42,43,44],"Post-traumatic wrist arthritis","Partial wrist fusions","Scapholunate advanced collapse","SLAC wrist","Scaphoid nonunion advanced collapse","SNAC wrist","Four-corner fusion","Bicolumnar wrist fusion","Three-corner fusion","Capitolunate fusion","RECRUITING","2026-06-19",{"date":48,"type":49},"2026-06-24","ACTUAL",{"date":51,"type":49},"2021-01-07",{"date":53,"type":20},"2027-04",{"name":55,"class":56},"University of Alberta","OTHER",5,{"id":59,"slug":4,"hasResults":10,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100641958","NCT07651735","Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Primary Hip Prosthesis System","A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Primary Hip Prosthesis System","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Male or female participants,\n* Subjects who have undergone Primary Hip Arthroplasty (either total or partial) for any indication,\n* Subjects in whose surgical procedure the Tipmed™ Primary Hip Prosthesis System components were utilized.\n* Subjects who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship).\n* Subjects who have voluntarily signed the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Subjects currently participating in any other interventional clinical trial.",{"count":65,"type":20},101,"OBSERVATIONAL","This is a multicenter, prospective, observational, post-market clinical follow-up (PMCF) study designed to evaluate the safety and clinical performance of the Tipmed™ Primary Hip Prosthesis System in adult subjects undergoing primary hip arthroplasty. The study aims to gather real-world clinical evidence on the 24-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.",[69,70,71,72,33],"Total Hip Arthroplasty (THA)","Hemiarthroplasty","Osteoarthritis (OA) of the Hip","Femoral Neck Fractures",[74,75,76,77,78,79],"Hip Prosthesis","Total Hip Prosthesis","Partial Hip Prosthesis","Primary Hip Arthroplasty","Post-Market Clinical Follow-Up (PMCF)","Harris Hip Score (HHS)","2026-06-10",{"date":82,"type":49},"2026-06-16",{"date":84,"type":49},"2024-03-12",{"date":86,"type":20},"2029-03-31",{"name":88,"class":89},"TIPMED Medical Device Manufacturing Ltd. Co.","INDUSTRY",4,{"id":92,"slug":4,"hasResults":10,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":10,"sex":15,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100643444","NCT07637916","Comparing Two Shoulder Treatments for Athletes","Comparative Effects of Kaltenborn Joint Mobilization (Posterior Glide) Versus Pragmatic Posterior Capsular Stretch on Pain, Limited ROM and Functional Disability in Athletes With Posterior Capsule Tightness","PCT-KM-PPS","Inclusion Criteria:\n\n* Male and female athletes\n* Positive GIRD test\n* Age 22-40 years\n* Overhead throwing athletes (Cricketers)\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Fracture\n* Recent shoulder injury (last 6 months)\n* History of shoulder surgery\n* Osteoarthritis\n* Peripheral nerve injuries","22 Years","40 Years",{"count":101,"type":20},34,[23],"Many athletes who play overhead sports like cricket develop tightness in the back of the shoulder. This causes pain and makes it hard to lift the arm. This study will compare two common physical therapy treatments: Kaltenborn joint mobilization (a specific manual therapy glide) versus a Pragmatic Posterior Capsular Stretch (a specific stretching technique). We want to see which one works better for pain, range of motion, and daily function. 28 athletes will be treated for 4 weeks, and we will measure their progress using a goniometer and the SPADI questionnaire.",[105,33,106],"Posterior Capsule Tightness","Joint Range of Motion",[105,108,109,110,111,112,113],"GIRD","Kaltenborn Mobilization","Pragmatic Stretch","Glenohumeral Joint","Athletes","Atheletic over head shoulder restrictions","NOT_YET_RECRUITING","2026-06-04",{"date":80,"type":49},{"date":118,"type":20},"2026-06-15",{"date":120,"type":20},"2026-09-01",{"name":122,"class":56},"University of Faisalabad",1,{"id":125,"slug":4,"hasResults":10,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":123},"100514587","NCT05980442","Comparative Study of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty","Randomized, Controlled, Single Center Observational Study to Compare the Safety and Performance of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty","ORMAK","Inclusion Criteria:\n\n* Indication for a TKA with a fixed-bearing total knee endoprosthesis\n* Written informed consent for participating in the clinical study\n\nExclusion Criteria:\n\n* Patient age \\\u003C18 years and \\>90 years\n* Patient not willing to participate at the follow-up\n* Pregnancy\n* retropatellar arthrosis requiring patella resurfacing\n* American Society of Anaesthesiologists (ASA) Classification \\>3","90 Years",{"count":133,"type":20},140,"Randomized, controlled, single center observational study to compare the safety and performance of navigation-assisted OrthoPilot Elite and robotic-assisted MAKO total knee arthroplasty (TKA). The aim of the study is the comparison of the clinical outcome between navigated and robotic-assisted TKA. The hypothesis of the study is that both treatments achieve similar results regarding functional and clinical aspects.",[136,33,137,138],"Osteoarthritis, Knee","Rheumatoid Arthritis of Knee","Posttraumatic Arthropathy",[140,141,142,143,144],"computer assisted orthopedic surgery","robotic assisted orthopedic surgery","orthopedic navigation","total knee arthroplasty","total knee replacement","2026-03-26",{"date":147,"type":49},"2026-03-27",{"date":149,"type":49},"2024-07-03",{"date":151,"type":20},"2028-12",{"name":153,"class":89},"Aesculap AG",{"id":155,"slug":4,"hasResults":10,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":123},"100403652","NCT04536103","Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry","MVMS_MRI","Inclusion Criteria:\n\nGroup 1\n\n1\\. Age \\> 18\n\nGroup 2\n\n1\\. Age 18-50\n\nGroup 3\n\n1. Age 18-50\n2. Sustain an acute full ACL tear in one knee; the contralateral knee uninjured\n3. Undergo ACL reconstructions and standard rehabilitation\n\nGroup 4\n\n1\\. Age 18-50\n\nExclusion Criteria:\n\nGroup 1\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n\nGroup 2\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. History of osteoarthritis and inflammatory arthritis\n4. Previous injury and\u002For surgery on either knee\n\nGroup 3\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. Inability to undergo standard pre- and post-injury\u002Foperative rehabilitation\n\nGroup 4\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. History of osteoarthritis and inflammatory arthritis\n4. Previous injury and\u002For surgery on either knee","50 Years",{"count":162,"type":20},88,"Currently the diagnosis of OA is based on radiographs and clinical findings, which is limited to detecting late-stage disease. There is a pressing, unmet clinical need for robust assessment of early changes in cartilage health. Towards this goal, extensive efforts are ongoing to develop quantitative MRI for cartilage matrix analysis. MR T1ρ and T2 relaxation times have shown to be promising imaging biomarkers for early cartilage degeneration and prediction of disease progression. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and quantification methods, and long acquisition times. The study aims to develop novel, fast and reproducible MR T1ρ and T2 relaxation time imaging methods on MR systems from multiple vendors and establish a platform for standardization and cross validation of these measures as a tool for clinical trials using such techniques. Following method validation, patients at risk for osteoarthritis will be tested.",[165,32,33,166,167,168],"Bone Diseases, Infectious","Osteoarthritis","ACL Tear","Cartilage Degeneration","2026-02-24",{"date":171,"type":49},"2026-02-27",{"date":173,"type":49},"2022-04-01",{"date":175,"type":20},"2026-12-28",{"name":177,"class":56},"Xiaojuan Li",{"id":179,"slug":4,"hasResults":10,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":90},"100589520","NCT06955481","Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1","Prospective, Single-arm, Multicenter Study to Evaluate the Performance of Navigated Total Knee Arthroplasty Using the OrthoPilot and the Software pheno4u TKA Level 1","TKA4U","Inclusion Criteria:\n\n* Indication for a TKA with the OrthoPilot® Navigation System with a Aesculap total knee endo-prosthesis\n* Written signed informed consent of patient\n* Willingness and mental ability to participate at the long-term follow-up examinations\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients \\\u003C 18 years or \\> 80 years\n* Patients unable to participate at the follow-up examination (physically, mentally)\n* Previous joint replacement at the index knee\n* ASA classification \\> 3 ( ASA I: A healthy patient without systemic diseases. ASA II: A patient with a mild systemic disease that is well controlled (e.g., well-controlled diabetes or hypertension). ASA III: A patient with a severe systemic disease that causes functional limitations (e.g., poorly controlled diabetes, COPD). ASA IV: A patient with a life-threatening systemic disease (e.g., severe heart failure, sepsis). ASA V: A dying patient who is not expected to survive without the operation. ASA VI: A deceased patient whose organs are being removed for donation.)","80 Years",{"count":187,"type":20},120,"The purpose of this PMCF study is to demonstrate the accuracy of navigation using the new pheno4uTKA Level 1 software for OrthoPilot Elite® and to evaluate its safety and performance.\n\nPatient-related outcome measures (PROM) will be acquired to investigate functional outcome and patient satisfaction.",[136,33,137,138],[191,192,193],"Navigation","Total Knee Arthroplasty","OrthoPilot","2025-11-14",{"date":196,"type":49},"2025-11-17",{"date":198,"type":49},"2025-10-07",{"date":200,"type":20},"2028-06",{"name":153,"class":89},{"id":203,"slug":4,"hasResults":10,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":15,"minAge":16,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":123},"100584002","NCT06883669","The Application of Artificial Intelligence in Wrist and Hand Joint Ultrasound","Establishment of an Artificial Intelligence Recognition System for Wrist and Hand Joint Ultrasound Images\u002FVideos and Its Assistance to Untrained Sonographers","(1) Research Subjects-for AI system establishment\n\nInclusion Criteria:\n\n1. Healthy volunteers with good compliance\n2. No history of disease on peripheral nerve, muscle, or tendons;\n3. No early - stage RA or history of RA.\n\nExclusion Criteria:\n\n1\\. Amputees or those with limb disabilities.\n\nIndividuals with poor compliance.\n\n(2) Research Subjects-for AI system validation\n\nInclusion Criteria:\n\n1\\. Sonographers with at least 2 years of ultrasound scanning experience\n\nExclusion Criteria:\n\n1\\. Those who have performed musculoskeletal ultrasound scanning or received related training",true,"100 Years",{"count":211,"type":20},500,"1. To develop an AI system that can automatically identify standard sections and save images during wrist and hand joint ultrasound scans, while labeling key anatomical structures.\n2. To recruit sonographers untrained in musculoskeletal ultrasound, train them in wrist and hand joint scans, and compare their scanning speed and image quality when using and not using the AI system.",[214,33],"Education",[216,217,218,219,220,221],"ultrasound","hand","medical education","artificial intelligence","deep learning","wrist","2025-03-31",{"date":224,"type":49},"2025-04-04",{"date":226,"type":49},"2021-01-01",{"date":228,"type":20},"2025-06-01",{"name":230,"class":56},"West China Hospital",{"id":232,"slug":4,"hasResults":10,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":123},"100560622","NCT06579547","Evaluating Replacement of Standard-of-care Low Dose Computer Tomography (CT) Scans With Radiation-free Bone Imaging by Deep-learning Augmented Zero Echo Time (DL-ZTE) Magnetic Resonance Tomography (MRT)","Single-center Prospective Comparison of Diagnostic Performance of Deep-learning Agumented UTE\u002FZTE MRI Sequences and Standard-of-care Low Dose CT for Rheumatologic Patients With Musculoskeletal Disease","DLZTECT","Inclusion Criteria:\n\n* Referral for a clinically indicated MRI examination of the musculoskeletal system to assess inflammatory and degenerative joint changes.\n* Willingness to sign the informed consent form.\n* No contraindications for a CT examination (e.g., claustrophobia).\n\nExclusion Criteria:\n\n* No signed informed consent form.\n* Patients under 18 years of age.\n* Pregnant women.\n* The calculated effective dose of the CT examination exceeds 5 mSv.",{"count":239,"type":20},100,[23],"The goal of this clinical trial is to determine how effectively bone structures of the human skeleton can be visualized using Deep Learning (DL) augmented Magnetic Resonance Imaging (MRI) in individuals with inflammatory and degenerative joint changes, compared to Computed Tomography (CT). MRI is a technique that operates without the use of X-rays. The main question it aims to answer is:\n\n1. Can DL MRI accurately depict bone structures as well as CT?\n2. Can DL MRI be used as an alternative to CT to avoid exposure to X-rays in the future?\n\nResearchers will compare DL MRI scans to CT scans to see if DL MRI can effectively replace CT in visualizing bone structures without the use of radiation.\n\nParticipants will:\n\n1. Undergo MRI scans of their skeletal system that will then be processed using DL.\n2. Undergo CT scans of the same body region for comparison purposes.",[33,243],"Joint Inflammation","2024-08-27",{"date":246,"type":49},"2024-08-30",{"date":248,"type":49},"2024-08-01",{"date":250,"type":20},"2026-07",{"name":252,"class":56},"Roman Guggenberger",{"id":254,"slug":4,"hasResults":10,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":208,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":261,"conditions":262,"keywords":279,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100557135","NCT06534177","Digital Diagnostics and Intervention Services for Parkinson's Disease","Development of Digital Diagnostics and Intervention Services for Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \\[stroke, multiple sclerosis, arthritis or osteoporosis\\]\n* Able to self-report history of daily gait freezing and\u002For festination for people with PD or gait and\u002For transfers affected by condition\n* Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands Healthy participants \\[Phase 1,2,3\\]\n* With no long-term conditions affecting movement\n* Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and\n* if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands\n\nExclusion Criteria:\n\n* Participants with long-term conditions affecting movement\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system Healthy participants\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system",{"count":260,"type":20},80,"People with Parkinson's have infrequent clinical consultation (once every 12-18 months) and limited rehabilitation.\n\nAssessment play an important role in these consultations to help clinicians understand patients' health status and disease progression necessary to adjust treatment plans. The current way of measuring is the UPDRS which needs a clinician to do this and takes 30 minutes. There is a strong need for more frequent and accurate Parkinson's assessments in the clinic and at home to detect changes early and then give appropriate support and drug and physiotherapy quickly. There is a need to develop good home digital physiotherapy tools to increase the amount of therapy. Here the investigators are testing new digital technologies to do these assessments in the home and clinic and a new digital physiotherapy device in the home. The investigators aim to conduct a clinical study with 50 people with Parkinson's (50 from UK) with the UPDRS, (a rating scale that is commonly used in clinical settings to evaluate the progression of Parkinson's disease) and 30 healthy adults. The investigators will develop and investigate if two new digital devices, one the MachineMD that measures eye movement and one the gaitQ that measures gait can be used instead of the MDS-UPDRS (motor) using digital gait and ophthalmic features in the clinic setting. The investigators will investigate the effect of a physiotherapy gait intervention gaitQ Tempo in the home context for two weeks and of doing the gait measure at home. The investigators will determine the potential of the gaitQ intervention to improve key gait metrics in order to collect clinical evidence and of using the gaitQ as a cuing system over a 2-week period on gait and other movement measures in the home and community",[263,264,265,33,32,266,267,268,269,270,271,272,273,274,275,276,31,277,278],"Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Parkinson Disease","Basal Ganglia Diseases","Movement Disorders","Synucleinopathies","Neuro-Degenerative Disease","Demyelinating Disease, Autoimmune, CNS","Demyelinating Disease","Autoimmune Diseases","Immune System Diseases","Bone Diseases, Metabolic","Bone Diseases","Osteoporosis","Multiple Sclerosis",[280,281,282,283,284],"parkinson's disease","osteoarthritis","stroke","MS","osteoporosis","2024-08-06",{"date":287,"type":49},"2024-08-09",{"date":289,"type":20},"2024-10-15",{"date":291,"type":20},"2026-03-01",{"name":293,"class":56},"University of Exeter",{"id":295,"slug":4,"hasResults":10,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":306,"conditions":307,"keywords":314,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":123},"100550785","NCT06451588","Fecal Microbiota Transplantation in Axial Spondyloarthritis","Donor Versus Autologous Fecal Microbiota Transplantation for Axial Spondyloarthritis: a Double Blind, Placebo-Controlled, Randomized Trial","MicroSpA","Inclusion Criteria:\n\n* Axial Spondyloarthritis according to the ASAS classification criteria\n* Active disease defined as ASDAS ≥2.1 with elevated CRP ≥4 OR active inflammation on MRI within the last 3 months\n* Onset of axial SpA within last 10 years\n* Unsatisfactory relief of NSAIDs\n* On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months\n\nExclusion Criteria:\n\n* Planned dose adjustment or change in immunomodulatory treatment the next 90 days\n* Disease or disorder with life expectancy of ≤5 years\n* Severe immune deficiency (acquired, congenital og du to medication)\n* Previous treatment with FMT\n* Regular use of opioids with the exception of codeine and tramadol\n* Any specific diagnosis that could explain or contribute to the patients back pain (e.g. tumor, fracture, infection or degenerative disease)\n* Inflammatory spinal disease other than axSpA\n* Severe psychiatric disorder, alcohol- or drug abuse\n* Active inflammatory bowel disease\n* Microscopic colitis, diverticulitis or ileus\n* Active psoriasis\n* Fibromyalgia\n* Abdominal surgery excluding appendectomy, cholecystectomy, hysterectomy, caesarian section, sapling-ooforectomy and hernia surgery\n* Malignant disease excluding basalioma and melanoma stage 1\n* Conditions with expected necessary treatment with antibiotics during the study period, e.g. periodontitis end ischemic digital ulcers\n* Treatment with antibiotics 12 weeks prior to study entry\n* Pregnancy, lactation or planned pregnancy within the next 3 months\n* Contraindications for rectal catheter insertion\n* Planned rehabilitation program the next 90 days\n* Limited ability to comply with protocol requirements, including biobank participation","65 Years",{"count":303,"type":20},99,[305],"PHASE2","Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints.\n\nIt has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy.\n\nThe goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy.\n\nThe main questions it aims to answer are:\n\n* Can FMT reduce disease activity in axial SpA?\n* Can FMT alleviate pain and reduce fatigue in axial SpA?\n* Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT?\n\nParticipants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.",[308,309,310,311,312,31,32,313,33],"Axial Spondyloarthritis","Ankylosing Spondylitis","Dysbiosis","Spondyloarthritis","Spondylitis","Spinal Disease",[308,315,316,317,318,319],"Microbiome","Fecal Microbiota Transplantation","Microbiota","FMT","RCT","2024-06-04",{"date":322,"type":49},"2024-06-11",{"date":324,"type":49},"2024-06-01",{"date":326,"type":20},"2026-03",{"name":328,"class":56},"University Hospital of North Norway",{"id":330,"slug":4,"hasResults":10,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":123},"100521834","NCT06074744","Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty","Subsartorial Saphenous Nerve Block (SSNB) Versus Femoral Nerve Block (FNB) in Primary Total Knee Arthroplasty (TKA) Combined With Infiltration Between Popliteal Artery and Capsule of the Knee (IPACK) - Where Are the Benefits?","Inclusion criteria:\n\n* age \\> 18yrs\n* primary TKA\n* BMI 35kg\u002Fm2 or less\n* able to give informed consent as documented by signature\n* clinical history without any contraindications for the planned intervention\n\nExclusion criteria:\n\n* age \\\u003C 18 years\n* revision-TKA\n* BMI \\>35kg\u002Fm2\n* absent contact information\n* inability or contraindications to undergo the investigated intervention (TKA, FNB, SSNB), - clinically significant concomitant diseases\n* pregnancy\n* inability to follow the procedures and follow-up procedures of the study (e.g. due to language problems, psychological disorders, dementia, living abroad, etc.\n* withdrawal from the study",{"count":336,"type":20},144,[23],"The goal of this clinical trial is to compare two different types of nerve blocks in patients undergoing surgery for primary Total Knee Arthroplasty. The main question aim to answer is:\n\n\\- is there a benefit in functional muscle power output of the leg?\n\nParticipants will be randomized into either the intervention group or the control group and:\n\n* receive Subsartorial Saphenous Nerve Block (SSNB) + IPACK in intervention group (group 1)\n* receive Femoral Nerve Block (FNB) + IPACK in control group (group 2)\n\nResearchers will compare the 2 groups to see if there are differences in :\n\n* functional muscle power output of the leg?\n* muscle function, mobility, clinical and radiological results, ROM, pain control (NRS), opioid consumption, length of hospital stay, patient satisfaction, mobility, reduction of costs?",[33,340],"Joint Pain",[342,343,344],"Subsartorial Saphenous Nerve Block (SSNB)","Femoral Nerve Block (FNB)","Total Knee Arthroplasty (TKA)","2024-03-07",{"date":84,"type":49},{"date":348,"type":49},"2023-11-30",{"date":350,"type":20},"2026-12",{"name":352,"class":56},"Luzerner Kantonsspital",{"id":354,"slug":4,"hasResults":10,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":10,"sex":15,"minAge":359,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":123},"100527046","NCT06142669","EVOLUTION® Revision STEMMED CS Post Market Clinical Follow-up Study Protocol","Post Market Clinical Follow-Up Study for EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur With the EVOLUTION® MP CS Tibial Insert","Inclusion Criteria:\n\n1. Has previously undergone or currently has been determined to undergo a revision knee arthroplasty that requires implantation of the components under study (EVOLUTION® Revision Tibial System and EVOLUTION® STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert)\n2. Decision to perform the study index surgery with the required study components is pre-determined regardless of the research;\n3. Previously implanted subjects must be enrolled within 3 years (+ 6 months) of their study index surgery\n4. Willing to voluntarily sign the informed consent form\n5. Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit.\n\nExclusion Criteria:\n\n1. Skeletally immature (less than 21 years of age) at time of implantation\n2. Has or had an overt infection at the time of implantation\n3. Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and\u002For inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable\n4. Currently enrolled in another clinical investigation which could affect the endpoints of this protocol\n5. Has or had documented substance abuse issues\n6. Has or had an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study\n7. Currently incarcerated or has impending incarceration\n8. Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol","21 Years",{"count":361,"type":20},45,"MicroPort (MPO) is conducting this PMCF study to evaluate the safety and effectiveness of its EVOLUTION® Revision Tibial System and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert. This type of study is required by regulatory authorities for all devices that have been approved in Europe to evaluate the medium and long-term clinical evidence.",[33],[365,366,367],"Knee Osteoarthritis","Revision Procedure","Knee arthroplasty","2024-01-19",{"date":370,"type":49},"2024-01-22",{"date":372,"type":49},"2023-10-31",{"date":374,"type":20},"2036-12",{"name":376,"class":89},"MicroPort Orthopedics Inc.",{"id":378,"slug":4,"hasResults":10,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":10,"sex":15,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":387,"briefSummary":389,"conditions":390,"keywords":401,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":123},"100473080","NCT05440240","Percutaneous Needle Fasciotomy +\u002F- Corticosteroid Injection for Dupuytren's Contracture","Percutaneous Needle Fasciotomy (PNF) +\u002F- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial","Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \\\u003C20° passive extension deficit (PED), is a prerequisite for inclusion.\n\nInclusion Criteria:\n\n* Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer\n* DC of either II-V finger\n* Well-defined\u002Fpalpable cord\n\nExclusion Criteria:\n\n* Legally incapacitated\n* Previous study inclusion with another finger ray\n* Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture \\\u003C 20° PED regardless of the deficit in the PIP or DIP joint\n* Previous hand surgery of the affected finger for any reason\n* Known allergy to the study medication\n* Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)\n* Pregnant or lactation\n* Insulin dependent diabetes mellitus\n* Ongoing systemic infection or local infection at the site of the procedure\n* Rheumatoid arthritis\n* Amyloidosis or mucopolysaccharidosis\n* Unable to communicate, cooperate or participate in follow-up","45 Years","99 Years",{"count":386,"type":20},400,[388],"PHASE4","Comparing percutaneous needle fasciotomy +\u002F- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.",[391,392,393,33,32,394,395,396,397,398,399,400],"Dupuytren Contracture","Dupuytren's Disease","Contracture","Fibroma","Neoplasm, Fibrous Tissue","Neoplasms, Connective Tissue","Neoplasms, Connective and Soft Tissue","Neoplasms by Histologic Type","Neoplasms","Connective Tissue Diseases",[402,403,404],"Percutaneous needle fasciotomy","Corticosteroid","Randomized controlled trial","2023-05-15",{"date":407,"type":49},"2023-05-17",{"date":409,"type":49},"2023-01-10",{"date":411,"type":20},"2030-03",{"name":413,"class":56},"Regionshospitalet Silkeborg",""]